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(salvage therapy), 2nd-remission, 2nd-relapse, 2nd-progression,
3rd-line treatment (salvage therapy) and dead. RESULTS: The
direct medical cost included diagnostic and stratiﬁcation
USD$2,152.01 ($2,016.77–$2,287.26); 1st-line CHOP [7.19
cycles (6.97–7.42)] USD$841.17 ($813.03–$869.31); R-CHOP
[7.20 cycles (6.32–8.08)] USD$17,823.19 ($12,670.83–
$22,975.55); 1st-salvage treatment (Bone Marrow Transplant,
BEAM scheme) USD$56,174.10; 2nd-salvage treatment ICE-
Scheme USD$18,162.34, DHAP-Scheme USD$4,138.10;
ESHAP-Scheme USD$3,730.22; and monthly cost of support
therapy and follow-up USD$382.15 ($301.74–$462.57). The
estimated management cost at the ﬁfth year was USD$59,785.68
for R-CHOP and USD$52,966.70 for CHOP. The CE rate for the
use of R-CHOP vs CHOP was USD$6,526.54 for each free-
progression year, a clear trend toward the use of monoclonal
antibody inclusion. CONCLUSIONS: Long term results are fun-
damental for any evaluation of NHL treatment scheme. Under
this scenario, the increase in the free-progression survival and
global survival, with R-CHOP a CE ratio under one GDP per-
capita in Mexico (USD$7,785.89—A WHO accepted threshold)
for every free-progression year gained and it is evident that this
treatment is cost-effective.
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OBJECTIVES: To determine whether use of chelation therapy in
patients with refractory anemia (RA) related to myelodysplastic
syndrome (MDS) is cost-effective relative to no chelation in
transfusion-dependent patients. METHODS: A 10-year cohort
model with monthly cycles was built to predict the health and
economic implications for patients receiving chelation therapy
with 20 mg/kg deferasirox compared with no chelation. The
model included increased risk of death with no chelation; major
adverse events (e.g., cardiac disease) were assumed non-
differential, thus excluded, in the base analysis. Risk of death was
determined based on published prognostic data from chelated
(overall median survival = 115 months from diagnosis) and non-
chelated (median = 51 months) patients. Costs and utilities were
applied in each cycle by WHO Risk Classiﬁcation. Unit costs,
obtained from US cost data sources, were used to calculate the
costs of medication, management and transfusions. Risks of
death and complications, life expectancy, resource use, initial
utility value and decrease in utility due to complications were
taken from published literature. Costs were discounted at 3% per
year; beneﬁts were not discounted. RESULTS: In the base case
analysis, when initial utility value was taken as 0.6 and cost of
deferasirox was assumed to be $70/day, costs per patient were
estimated at $97,619 with deferasirox vs. $28,712 with no che-
lation. Deferasirox was predicted to increase QALYs by 1.43
years per patient, resulting in ICER = $48,172/QALY gained.
Increasing the initial utility value to 1 resulted in an ICER of
$28,903. CONCLUSIONS: Chelation therapy with deferasirox
is predicted to result in higher QALYs and substantially fewer
adverse events due to excess iron accumulation at a reasonable
cost. Resulting cost-effectiveness ratios are estimated to be within
acceptable limits.
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OBJECTIVES: The decision to use a drug ﬁrst-line instead of
second-line (salvage therapy) could have a signiﬁcant clinical
outcome and economic impact especially in rare diseases with
high treatment costs such as acquired haemophilia. The aim of
this study is to compare the cost-effectiveness of ﬁrst-line versus
second-line use of recombinant activated factor VII (rFVIIa) in
the management of severe bleeds in patients with acquired hae-
mophilia. The perspective of the study is that of the United States
hospital authorities. METHODS: We modelled the economic
impact of different treatment strategies reported from the only
existing compassionate-use database containing data from 38
patients with acquired haemophilia for whom rFVIIa was used in
the management of 78 severe bleeding episodes from 1990–1995.
RESULTS: In 14 bleeds, rFVIIa was used as the ﬁrst-line therapy
with 100% success in controlling the bleeds, while a success rate
of 75% was reported for 64 bleeding episodes in which rFVIIa
was used as a salvage therapy. The mean treatment cost of rFVIIa
as the ﬁrst-line therapy was $362,906 compared to $416,793
when rFVIIa was used as a salvage therapy. Furthermore, the cost
per effectively treated bleed for the second-line strategy was
$545,113 compared to $362,468 for ﬁrst-line use. CONCLU-
SIONS: Based on these results, rFVIIa, as a ﬁrst-line therapy, is
the cost-effective treatment option in the management of severe
bleeding episodes in acquired haemophilia patients as compared
to second-line treatment strategies.
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OBJECTIVES: Failed Back Surgery Syndrome (FBSS) is a chronic
neuropathic pain disorder characterized by persistent lower back
and/or leg pain after lumbar spine surgery. We are developing
a cost-effectiveness study evaluating Spinal Cord Stimulation
(SCS) treatment compared to conventional medical management
(CMM) in FBSS patients. Here we report the baseline cost and
health-related quality of life (HR-QoL) data from a societal
perspective. METHODS: A prospective, pre-post, observational
study is ongoing in nine Italian centers. Enrolled patients will be
followed for two years. A questionnaire was developed to collect
clinical (NRS—pain Numerical Rating Scale), economic (visits,
drugs, diagnostic-tests, hospitalizations, productivity losses,
medical aids), and quality of life (EQ-5D, SF-36 and Oswestry)
patient outcomes and productivity losses for caregivers.
RESULTS: Eighty patients were enrolled (mean age 58; 58%
female). The mean NRS valued in the year before enrolment was
7.6  1.5. The average total cost per patient per month was
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€287.96: 55% private expenses and 45% charged to NHS. Hos-
pitalizations created the highest burden (22%, NHS) followed
by home-care and transport (both private). In the last year
26 patients (33%) varied their occupational status due to pain.
Fifty-eight (73%) patients required a caregiver; caregivers were
absent from work in 80% of cases. A strong impairment in
baseline HR-QoL was documented. Patients reported an average
value of 37 in the EQ-VAS (‘pain/discomfort’ and ‘usual activi-
ties’ are the most impaired domains), using the UK conversion
values the mean utility score was 0.07, using the Catalonian it
was 0.10. According to the Oswestry questionnaire, 44% of
patients were considered crippled and 39% severely disabled.
The physical role was the most impaired dimension as measured
with the SF-36. CONCLUSIONS: Our baseline analysis demon-
strates FBSS is a very expensive disease that severely impairs
HR-QoL. Future analyses will evaluate the cost-effectiveness of
SCS and CMM in the treatment of FBSS.
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OBJECTIVES: To evaluate the cost-effectiveness of fentanyl ITS
(iontophoretic transdermal system—IONSYSTM) versus epidural
analgesia (EA) or intravenous patient-controlled analgesia (IV-
PCA) for acute post-operative pain management (POPM) from a
Finnish hospital perspective. METHODS: The cost-effectiveness
of IONSYSTM was assessed using a decision analytic model esti-
mating costs (2008€) and POPM patient outcomes (pain relief,
minor and major POPM-related complications) from surgery
to discharge. Groups receiving 1, 2 or 3 day(s) of IV-PCA or EA
were compared to groups receiving respectively 1, 2 or 3 day(s)
of IONSYSTM. Pain relief data were derived from clinical trials
and published literature. Complication rates were predicted from
a longitudinal hospital database. Resource use included drugs,
consumables, equipment, POPM-related complications and staff
time, the latter derived from expert panels and a literature review.
Costs were based on ofﬁcial tariffs and price lists. RESULTS: The
costs of IONSYSTM for 1, 2 or 3-day groups were €1,825, €2,240
and €2,655. For 1 day of IV-PCA and 1, 2, 3 day(s) of EA
respectively, savings were €70, and €164, €167, €174. For 2 or 3
days of IV-PCA respectively additional costs were €19 and €105.
The percentage of complication-free patients was consistently
higher with IONSYSTM as regards minor and major complica-
tions with increment ranges of [1.44%, 3.95%] and [0.04%,
2.29%], respectively. The percentage of patients reporting no or
mild pain with IONSYSTM was the same as with IV-PCA and
lower than with epidural with respective increments for 1, 2 and
3-day groups of -4.02%, -4.33% and -5.26%. CONCLU-
SIONS: Compared to EA, IONSYSTM offers lower costs and
fewer complications. EA however offers improved pain relief.
Compared to IV-PCA, IONSYSTM dominates the 1-day group
and for the 2 and 3-day groups offers fewer complications at a
higher cost.
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OBJECTIVES: Health Technology Assessment to evaluate the
medical effectiveness and cost-effectiveness of bariatric surgical
procedures in the therapy of morbid obesity in adults compared
to standard interventions. METHODS: Systematic literature
review (published since 2001), targeting adult subjects with
morbid obesity (BMI >= 40 kg/m2 or BMI >= 35 kg/m2 with
severe comorbidities). Relevant publications are identiﬁed by
means of a structured search of 28 databases (e.g. Medline,
Embase, Cochrane Central) on November 12th, 2007. In addition
a manual search of identiﬁed reference lists was conducted. Titles
and abstracts of the identiﬁed publications have been indepen-
dently screened by two experts on evidence based medicine
and health economics. The methodological quality of included
studies have been assessed using the criteria recommended by
the Scottish Intercollegiate Guideline Network (SIGN) Grading
Review Group. Randomised as well as non-randomised studies
are included, case reports and series are not considered. The
methodological quality of the economic publications has been
assesed using checklists of the German Scientiﬁc Working Group
of Technology Assessment for Health Care and the methodologi-
cal guide of the EURONHEED project. RESULTS: Among 5910
retrieved publications, 25 medical articles and seven health eco-
nomic studies met the inclusion criteria. Among the included
medical publications are nine RCTs, 13 papers on non-
randomised clinical trials, and three systematic reviews with
meta-analysis. Within the economic assessment, three CEA and
four systematic reviews have been identiﬁed. Three of the non-
randomised studies assess bariatric vs. conventional procedures.
All other studies compare different surgical procedures among
each other. Follow-up time varies between one and ﬁve years in
the RCT and goes up to eleven years in one clinical trial. Both
medical studies assessing effectiveness of bariatric vs. conven-
tional procedures show a signiﬁcant greater weight loss after
surgery and decline in comorbidities. Diabetes incidence after ten
years is lower in the surgery group, but no signiﬁcant differences
can be seen for hypertension, dislipoproteinemia. Among the
economics publications, three studies evaluated the cost-
effectiveness of certain bariatric surgeries. One study examined
two bariatric operations, adjustable gastric banding and gastric
bypass, for the treatment of obesity in patients with Type 2
diabetes mellitusOne of the studies included deals with a com-
parison of GBP vs. no treatment, whereas the other compares the
two surgical procedures VBG and AGB among each other.
Furthermore, four systematic literature reviews are among the
included economic publications, estimating the cost-effectiveness
of bariatric treatments based on published data. The focus of
the reviews lies both, on the comparison of the cost-effectiveness
among the bariatric procedures, as well as on the comparison to
no treatment at all. CONCLUSIONS: The short and medium
term effectiveness of bariatric procedures on weight loss can be
assumed and is cost-effective. The weight loss is generally accom-
panied by a reduction of comorbidities, in particular diabetes,
and a decreased overall mortality. There is a lack of studies that
focus long term effects and costs. Therefore, based on the avail-
able literature no recommendation can be given with respect to
the choice of a certain bariatric procedure in usual care or to the
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